

June 29, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

**BSE LIMITED** 

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir / Madam,

Sub: Restart of Penicillin-G production at our Kakinada facility post receipt of 'Consent to Operate' from Andhra Pradesh Pollution Control Board – Reg.,

Ref.: Our intimation letter dated April 28, 2025 and May 26, 2025

With reference to our above-mentioned letter dated May 26, 2025 regarding the intimation of awaited renewal of 'consent to operate (CTO)' from Andhra Pradesh Pollution Control Board (APPCB) for our Penicillin-G manufacturing facility, at Kakinada, Andhra Pradesh, of Lyfius Pharma Private Limited (Lyfius), a wholly owned stepdown subsidiary of the Company, we are pleased to inform that Lyfius has re-started the production, with immediate effect, after receiving the CTO from APPCB today, June 29, 2025.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

## AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.